XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
License and Collaboration Agreements - Additional Information (Detail) (USD $)
 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Jun. 30, 2012
Dec. 31, 2012
Alimera
Dec. 31, 2011
Alimera
Dec. 31, 2012
Alimera
Dec. 31, 2011
Alimera
Dec. 31, 2009
Alimera
Jul. 31, 2011
Intrinsiq
Sep. 30, 2011
Intrinsiq
Dec. 31, 2012
Pfizer Collaboration Agreement
Dec. 31, 2011
Pfizer Collaboration Agreement
Dec. 31, 2012
Pfizer Collaboration Agreement
Dec. 31, 2011
Pfizer Collaboration Agreement
Jun. 30, 2011
Pfizer Collaboration Agreement
Jun. 30, 2008
Pfizer Collaboration Agreement
Dec. 31, 2012
Pfizer Collaboration Agreement
Minimum
Dec. 31, 2012
Pfizer Collaboration Agreement
Maximum
Dec. 31, 2012
Pfizer Collaboration Agreement Restated
Jun. 30, 2011
Pfizer Collaboration Agreement Restated
Dec. 31, 2012
Bausch and Lomb
Dec. 31, 2011
Bausch and Lomb
Dec. 31, 2012
Bausch and Lomb
Dec. 31, 2011
Bausch and Lomb
Jun. 30, 2012
Bausch and Lomb
Collaborative Agreements And Contracts [Line Items]                                                      
Consideration received in cash           $ 12,000,000   $ 12,000,000                         $ 10,050,000            
Accrued development cost liabilities           5,700,000   5,700,000                                      
Conditional note received           15,000,000   15,000,000                                      
Milestone payment upon FDA approval     25,000,000     25,000,000                                          
Share in future profits           50.00%                                          
Percentage of Company's share of future profits           20.00%                                          
Pre-profitability net losses percentage           20.00%                                          
Percentage of royalties           20.00%                                          
Percentage of non-royalty consideration received           33.00%                                          
Deferred revenue 5,700,000   5,700,000   6,000,000         18,300,000                     7,750,000            
Increased performance period                   21 months 15 days                 4 years 5 years 6 months              
Revenue related to agreement 195,000 204,000 364,000 1,665,000   19,000 23,000 38,000 54,000     1,100,000 101,000 182,000 251,000 470,000           3,300,000          
Research Funding                                 500,000 500,000                  
Upfront payment                                 2,300,000       2,300,000            
License option right                                 20,000,000                    
Development and sales performance milestone maximum                                 146,500,000                    
Deferred revenue                         6,700,000                            
Deferred revenue non-current 5,149,000   5,149,000   3,783,000               1,500,000   1,500,000                        
Royalty income 390,000 426,000 774,000 624,000                                     390,000 426,000 774,000 624,000  
Accounts receivable 948,000   948,000   967,000                                   390,000   390,000   442,000
Capital equipment assets     $ 36,000 $ 380,000             $ 223,000